Key points are not available for this paper at this time.
Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first-line chemotherapy. (Funded by Pfizer and Merck Darmstadt, Germany; JAVELIN Bladder 100 ClinicalTrials.gov number, NCT02603432.).
Powles et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: